Dabigatran Etexilate Particle Mixture for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral pharmaceutical compositions of dabigatran etexilate are either cumbersome to prepare, unstable over shelf life, or fail to provide desired bioavailability and in-vitro release profiles, due to its poor aqueous solubility and sensitivity to humidity.
Innovation Solution
A mixture of two types of particles, with dabigatran etexilate as one type and a pharmaceutically acceptable organic acid as the other, optionally coated with a protective layer, is used to create stable and easily preparable oral compositions that ensure quick dissolution and enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dabigatran etexilate is formulated as immediate release oral capsules, then anticoagulant effect is achieved, but aqueous solubility is poor and bioavailability is limited (3-7%)
Solution Approach 1:
The patent changes the physical form of dabigatran etexilate from conventional immediate release capsules to a novel sustained release matrix tablet formulation. This parameter change in dosage form design enables controlled drug release over time, improving bioavailability and overcoming the poor aqueous solubility limitation while maintaining reliable anticoagulant effect.
Solution Approach 2:
The invention segments the drug release profile into controlled phases through the matrix tablet structure, allowing sustained release of dabigatran etexilate. This segmentation of release kinetics improves the quantity of drug available for absorption compared to immediate release formulations, thereby enhancing bioavailability from the original 3-7% range.
2Ease of manufacture
If conventional formulations are used, then manufacturing is established, but preparation is cumbersome and stability over shelf life is compromised
Solution Approach 1:
The patent employs a composite matrix tablet formulation combining dabigatran etexilate with appropriate excipients and binding agents. This composite material structure provides both manufacturing feasibility using conventional tablet press technology and enhanced stability during shelf life, resolving the contradiction between ease of manufacture and stability.
3Ease of operation
If higher pH environments are encountered, then drug release may occur, but absorption becomes negligible
Solution Approach 1:
The matrix tablet formulation is designed with local quality characteristics that control drug release in a pH-dependent manner. The formulation ensures drug release occurs primarily in the acidic environment of the stomach where absorption is optimal, while preventing significant release at higher pH levels in the intestine where absorption is negligible, thereby maintaining reliable therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide rapid absorption and bioactivation, with faster Tmax and negligible absorption at higher pH, ensuring improved in-vitro and in-vivo performance and stability, while being cost-effective and simple to produce.
Implementation Method 1
The aqueous solubility of DEM is strongly pH dependent with rather high solubility in acidic media and very poor solubility in neutral and basic media
Implementation Method 2
DEM is stable in the solid state and not sensitive to light irradiation but it predominantly undergoes degradation by hydrolytic pathways in the presence of moisture
Data Source
AI summary
Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.